Gianmario Schierano1, Rosa Angela Canuto2, Mitzy Mauthe von Degerfeld3, Roberto Navone4, Bruno Peirone3, Giulio Preti1, Giuliana Muzio2. 1. Department of Surgical Science, C.I.R. Dental School, University of Torino, Via Nizza 230, 10126 Torino, Italy. 2. Department of Clinical and Biological Sciences, University of Torino, Corso Raffaello 30, 10125 Torino, Italy. 3. Department of Veterinary Sciences, University of Torino, Largo Paolo Braccini 2, Grugliasco, 10095 Torino, Italy. 4. Department of Medical Science, University of Torino, Via Santena 5, 10126 Torino, Italy.
Abstract
BACKGROUND: The biological factors involved in dental implant osseointegration need to be investigated to improve implant success. METHODS: Twenty-four implants were inserted into the tibias of six minipigs. Bone samples were obtained at 7, 14, and 56 days. Biomolecular analyses evaluated mRNA of BMP-4, -7, Transforming Growth Factor-β2, Interleukin-1β, and Osteocalcin in sites treated with rhBMP-7, Type 1 Collagen, or Fibronectin (FN). Inflammation and osteogenesis were evaluated by histological analyses. RESULTS: At 7 and 14 days, BMP-4 and BMP-7 increased in the sites prepared with rhBMP-7 and FN. BMP-7 remained greater at 56 days in rhBMP-7 and FN sites. BPM-4 at 7 and 14 days increased in Type 1 Collagen sites; BMP-7 increased from day 14. FN increased the TGF-β2 at all experimental times, whilst the rhBMP-7 only did so up to 7 days. IL-1β increased only in collagen-treated sites from 14 days. Osteocalcin was high in FN-treated sites. Neutrophilic granulocytes characterized the inflammatory infiltrate at 7 days, and mononuclear cells at 14 and 56 days. CONCLUSIONS: This initial pilot study, in a novel way, evidenced that Type 1 Collagen induced inflammation and did not stimulate bone production; conversely FN or rhBMP-7 showed neo-osteogenetic and anti-inflammatory properties when directly added into implant bone site.
BACKGROUND: The biological factors involved in dental implant osseointegration need to be investigated to improve implant success. METHODS: Twenty-four implants were inserted into the tibias of six minipigs. Bone samples were obtained at 7, 14, and 56 days. Biomolecular analyses evaluated mRNA of BMP-4, -7, Transforming Growth Factor-β2, Interleukin-1β, and Osteocalcin in sites treated with rhBMP-7, Type 1 Collagen, or Fibronectin (FN). Inflammation and osteogenesis were evaluated by histological analyses. RESULTS: At 7 and 14 days, BMP-4 and BMP-7 increased in the sites prepared with rhBMP-7 and FN. BMP-7 remained greater at 56 days in rhBMP-7 and FN sites. BPM-4 at 7 and 14 days increased in Type 1 Collagen sites; BMP-7 increased from day 14. FN increased the TGF-β2 at all experimental times, whilst the rhBMP-7 only did so up to 7 days. IL-1β increased only in collagen-treated sites from 14 days. Osteocalcin was high in FN-treated sites. Neutrophilic granulocytes characterized the inflammatory infiltrate at 7 days, and mononuclear cells at 14 and 56 days. CONCLUSIONS: This initial pilot study, in a novel way, evidenced that Type 1 Collagen induced inflammation and did not stimulate bone production; conversely FN or rhBMP-7 showed neo-osteogenetic and anti-inflammatory properties when directly added into implant bone site.
Entities:
Keywords:
bone morphogenetic proteins; cytokines; dental implant; fibronectin; rhBMP-7; type 1 collagen
Authors: J F Mano; G A Silva; H S Azevedo; P B Malafaya; R A Sousa; S S Silva; L F Boesel; J M Oliveira; T C Santos; A P Marques; N M Neves; R L Reis Journal: J R Soc Interface Date: 2007-12-22 Impact factor: 4.118
Authors: Shundong Miao; Wenjian Weng; Zhongli Li; Kui Cheng; Piyi Du; Ge Shen; Gaorong Han Journal: J Mater Sci Mater Med Date: 2008-08-14 Impact factor: 3.896
Authors: P Chatakun; R Núñez-Toldrà; E J Díaz López; C Gil-Recio; E Martínez-Sarrà; F Hernández-Alfaro; E Ferrés-Padró; L Giner-Tarrida; M Atari Journal: Cell Mol Life Sci Date: 2013-04-09 Impact factor: 9.261
Authors: Nansi López-Valverde; Javier Aragoneses; Antonio López-Valverde; Cinthia Rodríguez; Bruno Macedo de Sousa; Juan Manuel Aragoneses Journal: Front Bioeng Biotechnol Date: 2022-07-22